Coherus Oncology, Inc. (CHRS) vs PepGen, Inc. (PEPG)
Coherus Oncology, Inc. and PepGen, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and PepGen, Inc. are of similar size ($185.6M and $183.9M). PepGen, Inc. has the higher net margin (0.00% vs −259.4%) and the lower return on invested capital (−2,076.3% vs 0.00%). Across the 15 metrics below, PepGen, Inc. leads on 9 and Coherus Oncology, Inc. on 6.
Valuation
Profitability
| Metric | CHRS | PEPG | Biotechnology median |
|---|---|---|---|
| Gross margin | 68.94% | 0.00% | 65.16% |
| Operating margin | (311.56%) | 0.00% | 0.00% |
| Net margin | (259.41%) | 0.00% | 0.00% |
| Free cash flow margin | (365.22%) | 0.00% | 0.00% |
| Return on equity | (146.27%) | (75.45%) | (57.72%) |
| Return on assets | (41.90%) | (59.06%) | (49.22%) |
| Return on invested capital | 0.00% | (2,076.25%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack